LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.45 CNY | +1.14% |
|
-1.76% | -12.49% |
| Apr. 29 | Liaoning Chengda Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 24 | Tech Sector Galvanizes Asian Stock Markets | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 12,668 | 13,539 | 11,746 | - | - |
| Enterprise Value (EV) 1 | 12,668 | 13,539 | 11,746 | 11,746 | 11,746 |
| P/E ratio | 17.7 x | - | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 7.74 x | 6.63 x | 6.29 x | 5.77 x |
| EV / Revenue | - | 7.74 x | 6.63 x | 6.29 x | 5.77 x |
| EV / EBITDA | - | 19.3 x | 18.9 x | 18.2 x | 17 x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | 1.22 x | 1.18 x | 1.13 x |
| Nbr of stocks (in thousands) | 416,450 | 416,450 | 412,856 | - | - |
| Reference price 2 | 30.42 | 32.51 | 28.45 | 28.45 | 28.45 |
| Announcement Date | 2/24/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 1,750 | 1,771 | 1,867 | 2,034 |
| EBITDA 1 | - | 701.7 | 620 | 645 | 689 |
| EBIT 1 | - | - | 543 | 568 | 609 |
| Operating Margin | - | - | 30.66% | 30.42% | 29.94% |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | 714.8 | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | 1.720 | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 2/24/23 | 2/23/24 | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 4.84% | 4.8% | 4.8% | 5% |
| ROA (Net income/ Total Assets) | - | 4.66% | 4.5% | 4.6% | 4.7% |
| Assets | - | - | - | - | - |
| Book Value Per Share 1 | - | - | 23.40 | 24.20 | 25.10 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 2 | - | 552 | 148 | 149 | 170 |
| Capex / Sales | - | 31.54% | 8.36% | 7.98% | 8.36% |
| Announcement Date | 2/24/23 | 2/23/24 | - | - | - |
1CNY2CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
28.45
CNY
Average target price
32
CNY
Spread / Average Target
+12.48%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.49% | 1.61B | |
| -2.32% | 92.59B | |
| +3.68% | 41.43B | |
| -11.26% | 33.49B | |
| -19.30% | 14.62B | |
| -9.01% | 12.77B | |
| -11.34% | 11.58B | |
| -43.53% | 11.35B | |
| +3.75% | 8.97B | |
| -6.32% | 8.3B |
- Stock Market
- Equities
- 688739 Stock
- Financials Liaoning Chengda Biotechnology Co.,Ltd.
